Aptevo Therapeutics Inc.

NasdaqCM:APVO Stock Report

Market Cap: US$2.3m

Aptevo Therapeutics Management

Management criteria checks 3/4

Aptevo Therapeutics' CEO is Marvin White, appointed in Aug 2016, has a tenure of 8.42 years. total yearly compensation is $873.45K, comprised of 64.7% salary and 35.3% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $184.40. The average tenure of the management team and the board of directors is 3 years and 8.4 years respectively.

Key information

Marvin White

Chief executive officer

US$873.4k

Total compensation

CEO salary percentage64.7%
CEO tenure8.4yrs
CEO ownership0.008%
Management average tenure3yrs
Board average tenure8.4yrs

Recent management updates

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

May 26

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Dec 02

Aptevo gets $50/share takeout offer from shareholder Tang

Nov 18

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Nov 09

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

CEO Compensation Analysis

How has Marvin White's remuneration changed compared to Aptevo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$873kUS$565k

-US$19m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

US$17m

Dec 31 2022US$1mUS$565k

US$7m

Sep 30 2022n/an/a

US$6m

Jun 30 2022n/an/a

US$6m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$565k

-US$29m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$971kUS$498k

-US$31m

Sep 30 2020n/an/a

-US$33m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$974kUS$547k

-US$43m

Sep 30 2019n/an/a

-US$48m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$1mUS$565k

-US$54m

Compensation vs Market: Marvin's total compensation ($USD873.45K) is above average for companies of similar size in the US market ($USD643.82K).

Compensation vs Earnings: Marvin's compensation has been consistent with company performance over the past year.

CEO

Marvin White (62 yo)

8.4yrs

Tenure

US$873,446

Compensation

Mr. Marvin L. White has been an Independent Director at Emergent BioSolutions Inc. since 2022 and served as its Director since October 1, 2020 until 2022. Mr. White has been the Chief Executive Officer, Pr...

Leadership Team

NamePositionTenureCompensationOwnership
Marvin White
President8.4yrsUS$873.45k0.0082%
$ 184.4
Jeffrey Lamothe
Executive VP & COO1.8yrsUS$741.59k0.0064%
$ 144.1
SoYoung Kwon
Senior VP3.5yrsUS$654.73k0.0044%
$ 99.1
Daphne Taylor
Senior VP & CFO1.8yrsno data0.0032%
$ 72.0
Dirk Huebner
Chief Medical Officer3yrsno datano data

3.0yrs

Average Tenure

58yo

Average Age

Experienced Management: APVO's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marvin White
President8.4yrsUS$873.45k0.0082%
$ 184.4
Daniel Abdun-Nabi
Independent Director8.4yrsUS$73.21k0.0014%
$ 31.5
Zsolt Harsanyi
Independent Director8.4yrsUS$93.21k0.0016%
$ 36.0
John Niederhuber
Independent Chairman8.4yrsUS$88.21k0.0012%
$ 27.0
Barbara Kunz
Independent Director8.4yrsUS$78.21k0.0010%
$ 22.5
Grady Grant
Independent Director8.4yrsUS$70.71k0.0010%
$ 22.5

8.4yrs

Average Tenure

68.5yo

Average Age

Experienced Board: APVO's board of directors are considered experienced (8.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 11:36
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptevo Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangzhi LiLadenburg Thalmann & Company
Edward TenthoffPiper Sandler Companies
Jonathan AschoffRoth Capital Partners